Salud financiera de hoja de balance de Elutia

Salud financiera controles de criterios 0/6

Elutia tiene un patrimonio de los accionistas total de $-38.6M y una deuda total de $23.7M, lo que sitúa su ratio deuda-patrimonio en -61.3%. Sus activos y pasivos totales son $43.4M y $82.0M respectivamente.

Información clave

-43.8%

Ratio deuda-patrimonio

US$22.01m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$12.55m
Patrimonio	-US$50.30m
Total pasivo	US$85.66m
Activos totales	US$35.36m

Actualizaciones recientes sobre salud financiera

Recent updates

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

Análisis de la situación financiera

Pasivos a corto plazo: ELUT tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: ELUT tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ELUT tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: ELUT tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ELUT tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ELUT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 20.8% cada año

Salud financiera de hoja de balance de Elutia

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

Aziyo Biologics Receives Notice from Nasdaq Stating Non Compliance with Nasdaq Listing Rule 5450(B)(1)(A)

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Elutia Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Shareholder dilution

Elutia Inc., Annual General Meeting, Jun 06, 2024

New major risk - Shareholder dilution

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Elutia Inc. to Report Q4, 2023 Results on Mar 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance

Consensus revenue estimates increase by 17%

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT).

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Elutia Inc. to Report Q3, 2023 Results on Nov 13, 2023

Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC

New major risk - Shareholder dilution

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

Aziyo Biologics, Inc. Provides Net Sales Guidance for the Full Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Aziyo Biologics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Aziyo Biologics, Inc. announced that it has received $13.999976 million in funding

Aziyo Biologics, Inc. announced that it expects to receive $13.999976 million in funding

Aziyo Biologics Receives Notice from Nasdaq Stating Non Compliance with Nasdaq Listing Rule 5450(B)(1)(A)

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$15.79 loss in 3Q 2020)

Price target decreased to US$15.00

Price target decreased to US$15.75

Price target decreased to US$15.75

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$7.99 loss in 2Q 2020)

Aziyo Biologics, Inc.(NasdaqGM:AZYO) dropped from Russell Microcap Value Index

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway